Freenome与罗氏达成独家协议拓展技术合作以开发和商业化美国以外的癌症筛查测试

投资观察11-18

罗氏控股有限公司：*FREENOME：宣布与罗氏达成独家协议，以扩大技术合作，开发和商业化美国以外的癌症筛查测试。*FREENOME：保留美国以外集中测试的权利，以及所有美国的权利，但须遵循与精密科学（Exact Sciences）之前的许可协议。*FREENOME：价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) 来源日期/时间 = 2025-11-18 14:00:06.74 GMT

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1156918800?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-18 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156918800","market":"us","top_or_hot":-1,"title":"Freenome与罗氏达成独家协议 拓展技术合作以开发和商业化美国以外的癌症筛查测试","media":"投资观察","content":"<p>罗氏控股有限公司：*FREENOME：宣布与罗氏达成独家协议，以扩大技术合作，开发和商业化美国以外的癌症筛查测试。*FREENOME：保留美国以外集中测试的权利，以及所有美国的权利，但须遵循与精密科学（Exact Sciences）之前的许可协议。*FREENOME：价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) 来源日期/时间 = 2025-11-18 14:00:06.74 GMT</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Freenome与罗氏达成独家协议 拓展技术合作以开发和商业化美国以外的癌症筛查测试</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFreenome与罗氏达成独家协议 拓展技术合作以开发和商业化美国以外的癌症筛查测试\n</h2>\n\n<h4 class=\"meta\">\n\n2025-11-18 22:21 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>罗氏控股有限公司：*FREENOME：宣布与罗氏达成独家协议，以扩大技术合作，开发和商业化美国以外的癌症筛查测试。*FREENOME：保留美国以外集中测试的权利，以及所有美国的权利，但须遵循与精密科学（Exact Sciences）之前的许可协议。*FREENOME：价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor ...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"","article_id":"1156918800","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156918800","pubTimestamp":1763475697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"罗氏控股有限公司：*FREENOME：宣布与罗氏达成独家协议，以扩大技术合作，开发和商业化美国以外的癌症筛查测试。*FREENOME：保留美国以外集中测试的权利，以及所有美国的权利，但须遵循与精密科学（Exact Sciences）之前的许可协议。*FREENOME：价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) 来源日期/时间 = 2025-11-18 14:00:06.74 GMT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4548":"巴美列捷福持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","EXAS":"精密科学","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Freenome and Roche enter exclusive agreement to expand technology collaboration to develop and commercialize cancer screening tests outside the US","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"罗氏控股有限公司：*FREENOME：宣布与罗氏达成独家协议，以扩大技术合作，开发和商业化美国以外的癌症筛查测试。*FREENOME：保留美国以外集中测试的权利，以及所有美国的权利，但须遵循与精密科学（Exact Sciences）之前的许可协议。*FREENOME：价值超过2亿美元的协议包括7500万美元的股权工具、里程碑付款及美国以外测试销售的版税。((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com)) 来源日期/时间 = 2025-11-18 14:00:06.74 GMT","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156918800","isCrawlerRequest":true}

Freenome与罗氏达成独家协议 拓展技术合作以开发和商业化美国以外的癌症筛查测试

精彩评论

Freenome与罗氏达成独家协议拓展技术合作以开发和商业化美国以外的癌症筛查测试